Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masashi Narazaki

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|May 19, 2005
Targeting coagulation to the tumor microvasculature: perspectives and therapeutic implications from preclinical studiesMasashi Narazaki, Giovanna Tosato
Expert Review of Clinical Pharmacology|July 6, 2022
Current status and prospects of IL-6-targeting therapyMasashi Narazaki, Tadamitsu Kishimoto
Blood|January 21, 2006
Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3AMasashi Narazaki, Giovanna Tosato
International Journal of Molecular Sciences|November 15, 2018
The Two-Faced Cytokine IL-6 in Host Defense and DiseasesMasashi Narazaki, Tadamitsu Kishimoto
Cancer Journal (Sudbury, Mass.)|April 25, 2006
Canstatin: an inhibitor of angiogenesis and tumor growth revisitedMasashi Narazaki, Giovanna Tosato
Journal of the National Cancer Institute|March 2, 2006
Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us whyMasashi Narazaki, Giovanna Tosato
Journal of the National Cancer Institute|June 8, 2006
Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth?Masashi Narazaki, Giovanna Tosato
Immunotherapy|July 7, 2016
Immunotherapeutic implications of IL-6 blockade for cytokine stormToshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto
Cold Spring Harbor Perspectives in Biology|September 6, 2014
IL-6 in inflammation, immunity, and diseaseToshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto
Cold Spring Harbor Perspectives in Biology|August 6, 2017
Interleukin (IL-6) ImmunotherapyToshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|May 19, 2005
Targeting coagulation to the tumor microvasculature: perspectives and therapeutic implications from preclinical studiesMasashi Narazaki, Giovanna Tosato
Expert Review of Clinical Pharmacology|July 6, 2022
Current status and prospects of IL-6-targeting therapyMasashi Narazaki, Tadamitsu Kishimoto
Blood|January 21, 2006
Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3AMasashi Narazaki, Giovanna Tosato
International Journal of Molecular Sciences|November 15, 2018
The Two-Faced Cytokine IL-6 in Host Defense and DiseasesMasashi Narazaki, Tadamitsu Kishimoto
Cancer Journal (Sudbury, Mass.)|April 25, 2006
Canstatin: an inhibitor of angiogenesis and tumor growth revisitedMasashi Narazaki, Giovanna Tosato
Journal of the National Cancer Institute|March 2, 2006
Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us whyMasashi Narazaki, Giovanna Tosato
Journal of the National Cancer Institute|June 8, 2006
Conflicting results from clinical observations and murine models: what is the role of plasminogen activators in tumor growth?Masashi Narazaki, Giovanna Tosato
Immunotherapy|July 7, 2016
Immunotherapeutic implications of IL-6 blockade for cytokine stormToshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto
Cold Spring Harbor Perspectives in Biology|September 6, 2014
IL-6 in inflammation, immunity, and diseaseToshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto
Cold Spring Harbor Perspectives in Biology|August 6, 2017
Interleukin (IL-6) ImmunotherapyToshio Tanaka, Masashi Narazaki, Tadamitsu Kishimoto
Pageof 8